Sponsored genetic testing programs can run afoul of federal laws, including the FCA and AKS, if not designed correctly.

In this episode, Host Erin Harris sits down with Dr. Simrit Parmar, Founder of Cellenkos, to explore how the company is pioneering umbilical cord blood-derived Regulatory T cell (Treg) cell therapies ...

New treatment paradigms are making biopharma industry stakeholder communications more ambitious and complex. But they must ...

Tom Chalberg, Ph.D., co-founder of Genascence, explains how gene therapies are moving beyond the confines of rare diseases and into a wider range of indications.

Oxygen, crucial for cellular respiration, is affected by pressure variations within a bioreactor, with higher pressure at the bottom leading to increased oxygen solubility. This heterogeneity is ...

Given the near-constant technological advancements in AI, potential AI policy updates, and regulatory changes, flexible AI ...

CEO Peter Anastasiou describes the science behind Capsida’s platform, current pipeline, and why they chose to manufacture in-house.

LB Pharmaceuticals CEO Heather Turner explains why 18 years as a general counsel provided her with an advantageous ...